Cardinal Health Inc. Stock (US14149Y1082): Analyst Targets and Valuation Under the Microscope

Cardinal Health shares trade near recent highs as Wall Street price targets imply further upside. A look at the latest analyst targets, valuation metrics and what they signal for the NYSE-listed distributor.

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 16, 2026 at 7:09 PM ET. Details in the imprint.

Cardinal Health Inc. stock remains in focus this week as Wall Street analyst price targets continue to imply additional upside from current levels, keeping the NYSE-listed healthcare distributor on the radar of many U.S. retail investors. With the shares recently changing hands around the mid-$220 range in New York trading, consensus targets compiled by MarketBeat suggest a roughly 9 percent appreciation potential over the coming 12 months. Against this backdrop, investors are weighing how those targets line up with the company’s fundamentals, earnings power and position in the U.S. healthcare supply chain.

What the latest analyst targets say about Cardinal Health

According to MarketBeat data, Cardinal Health carries a consensus 12-month price target of about $246.93 per share, based on the latest published estimates from 17 covering analysts. That average target implies approximately 9.01 percent upside compared with a recent closing price of $226.52 as of the most recent session cited in the compilation. Within that group, the highest individual target sits at $275.00, while the lowest stands at $208.00, highlighting a reasonably wide but still constructive range of opinions on the stock.

The presence of 17 active analyst targets underlines that Cardinal Health remains closely followed among large U.S.-listed healthcare names, even though it is primarily a distribution and services business rather than a high-profile drug manufacturer or biotech. While MarketBeat does not assign the targets itself, it aggregates published research from major brokerages and investment banks, providing a snapshot of how the Street currently values the stock. For U.S. retail investors, that consensus view often serves as a reference point when comparing an individual company’s prospects to broader healthcare sector expectations.

The gap between the current share price and the average target reflects analysts’ views on Cardinal Health’s earnings trajectory, margin profile and cash generation relative to peers in drug distribution and medical products. In simple terms, a positive implied return suggests that, on balance, analysts expect either earnings growth, some degree of multiple expansion, or a combination of both over the coming year. However, the spread between the highest and lowest targets also signals that there is no unanimous view on how much room is left for the stock to run, which is typical for a company operating in a complex and tightly regulated segment like healthcare distribution.

Beyond the numerical targets, the dispersion can also reflect differing assumptions about factors such as generic drug pricing trends, manufacturer rebate dynamics and potential changes in healthcare policy in the United States. Analysts more optimistic on these variables may gravitate toward the upper end of the price range, while those focusing on reimbursement pressure or competitive intensity might set more cautious objectives. For investors, understanding that a single consensus number is an average of varied underlying theses is as important as the headline figure itself.

How valuation lines up with Cardinal Health’s fundamentals

Fundamental snapshots from platforms such as Pluang show Cardinal Health generating very large top-line revenue, reflecting its role as a major distributor within the U.S. healthcare system. Recent data on that site list annual revenue of about $250.74 billion, with gross profit around $9.42 billion and net income near $1.56 billion. On a per-share basis, Pluang cites earnings per share of roughly $1.69 and an EBITDA figure of about $3.27 billion. While these figures may not be in real time, they illustrate the scale at which the company operates and the relatively thin margins that are typical in drug distribution.

Distribution businesses like Cardinal Health tend to report high revenues but operate on narrow gross and operating margins, as they primarily earn a spread on the products they move rather than large markups on sales. That structure means even modest improvements in margin or incremental efficiency gains can have a meaningful impact on net income and cash flow. Conversely, small adverse movements in pricing or cost structure can weigh on profitability. Analysts assessing valuation often pay close attention to the stability of these margins and management’s ability to offset cost pressures through scale, automation and supply chain optimization.

In addition, valuation comparisons frequently consider earnings multiples and enterprise value relative to EBITDA for Cardinal Health and key U.S. peers in the wholesale and distribution segment. Platforms that track fundamentals, including Pluang, highlight the company’s earnings and EBITDA base, which analysts then use as inputs for discounted cash flow models or peer multiple comparisons. When the consensus price target sits above the prevailing share price, as is currently the case, it generally indicates that analysts see the present valuation as not fully reflecting those earnings and cash flow prospects.

Investors also often look at how Cardinal Health’s valuation compares to major U.S. healthcare indices and diversified distributors in terms of price-to-earnings and price-to-sales ratios. Because the business is heavily volume-driven, revenue-based metrics can at times appear low compared with higher-margin healthcare companies, which is why many analysts favor earnings and cash flow measures when forming target prices. The combination of strong revenue scale and modest margins tends to result in valuation multiples that look different from those of pharmaceutical manufacturers or medical device makers, underscoring the importance of comparing Cardinal Health with appropriate industry peers.

Trading backdrop: options interest and technical picture

Alongside fundamental and target-price discussions, derivatives activity has recently drawn attention to Cardinal Health. Investing.com reported elevated options trading volume focused on puts in recent trading, with options contracts numbering in the low thousands by early afternoon New York time on a recent Monday session. While the report did not specify a single catalyst driving that activity, higher put volume can sometimes signal increased hedging by existing shareholders or speculative positioning by traders anticipating volatility.

Options flow by itself does not determine the future direction of the underlying stock, but it can serve as an indicator of how active market participants are in seeking downside protection or directional exposure. In the case of Cardinal Health, the focus on put contracts mentioned in the Investing.com note suggests that at least some market participants were attentive to potential short-term swings in the share price, despite the generally constructive analyst target backdrop. For retail investors, such data can be a reminder that institutional and professional traders may be expressing more nuanced views through derivatives than are apparent from spot price moves alone.

Technical indicators also show that the stock has been trading near multi-week highs. German financial portal finanzen.net, which tracks international listings including U.S. stocks, recently flagged Cardinal Health shares as hitting new 4-week highs on June 10, 2026, and again on June 11, 2026. Those milestones confirm that the stock has been in an upward trend over the past month, consistent with a pattern of strength that aligns with the positive consensus price targets. However, fresh highs can also prompt some investors to lock in gains, which may partly explain the interest in put options as a hedge.

From a broader market perspective, Cardinal Health trades on the New York Stock Exchange under the ticker symbol CAH and is generally considered part of the large-cap U.S. healthcare universe. While index membership details were not explicitly stated in the sources reviewed, the company’s market capitalization and trading profile place it alongside other widely followed healthcare names that feature in major U.S. equity benchmarks. For investors monitoring sector rotation and factor trends, that positioning means the stock can be influenced both by company-specific news and by flows tied to healthcare and defensive-sector allocations.

Business profile and strategic positioning in healthcare

Cardinal Health describes itself as a healthcare services and products company that links manufacturers and providers across the care continuum, including hospitals, pharmacies and other healthcare settings. The company’s core operations span pharmaceutical distribution, medical products and related services, enabling customers to access a wide range of medications and supplies. As a large intermediary between drug manufacturers and end providers, Cardinal Health plays a critical role in ensuring that products move efficiently through the supply chain in the United States and other markets.

The pharmaceutical distribution segment typically generates the majority of Cardinal Health’s revenue, reflecting the high volume of drugs and related products it delivers on behalf of manufacturers. In addition to simply moving product, the company offers inventory management, data analytics and logistics support, which can enhance the efficiency and reliability of deliveries to hospital systems and retail pharmacies. The medical segment, which includes devices, disposables and specialty products, provides another revenue stream that may have different margin characteristics and competitive dynamics.

In terms of strategy, Cardinal Health has historically focused on optimizing its distribution footprint, investing in technology and data capabilities, and partnering with key stakeholders to provide more integrated solutions. These efforts aim to improve service quality for providers while also capturing efficiencies that can support margins in a competitive environment. At the same time, the company must manage risks related to pricing pressure, regulatory changes, and shifts in healthcare utilization patterns, all of which factor into analysts’ long-term valuation models and price targets.

As a U.S.-based company, Cardinal Health is exposed to domestic policy developments, including potential changes in drug pricing regulations, reimbursement frameworks and broader healthcare reform debates. Analysts assessing the stock’s medium-term outlook often incorporate scenarios around these policy variables, as they can influence both revenue growth and profitability. For example, tighter reimbursement structures or increased scrutiny on distribution fees could weigh on earnings, while favorable policy outcomes might support volume growth and reinforce the company’s role as an efficient conduit in the healthcare system.

How analyst views interact with market risks

When comparing consensus price targets to current trading levels, it is important to recognize that analyst models are inherently sensitive to assumptions about revenue growth, margin trends and capital allocation. For Cardinal Health, revenue expectations are closely tied to prescription drug volumes, healthcare utilization and the company’s ability to maintain or gain share in key distribution channels. Margin assumptions depend on cost management, contract terms with manufacturers and providers, and the impact of any investments in technology, infrastructure or acquisitions.

Analysts also monitor the company’s balance sheet, focusing on leverage levels, liquidity and capital return policies. While the sources reviewed did not detail specific debt metrics or dividend levels, these factors typically influence how much flexibility a company has to pursue share repurchases, raise dividends or fund strategic initiatives. Higher leverage or significant capital commitments can constrain that flexibility and may lead analysts to apply more conservative valuation multiples, even if near-term earnings look solid.

Risk factors specific to Cardinal Health’s business model include potential disruptions in the supply chain, changes in relationships with large customers and manufacturers, and exposure to litigation or regulatory investigations common in the healthcare sector. Though the current analyst target consensus appears constructive, any adverse developments in these areas could weigh on sentiment and lead to downward revisions in future target updates. Conversely, stronger-than-expected execution on strategic initiatives, better margin performance or favorable legal outcomes could prompt upward revisions to targets over time.

Options market activity, such as the put-focused trading reported by Investing.com, can sometimes hint at near-term caution even when long-term analyst targets remain positive. That divergence underscores the difference between short-term trading sentiment and the multi-quarter perspective embedded in most equity research models. For investors, understanding that analyst targets are not static and can move with new information is crucial when using them as part of a broader decision-making framework.

Context for U.S. retail investors watching Cardinal Health

For U.S. retail investors, Cardinal Health offers exposure to the healthcare distribution and services segment rather than direct product innovation like branded pharmaceuticals or cutting-edge biotech therapies. This distinction matters because the drivers of shareholder value can differ meaningfully. While product companies may see earnings hinge on the success of a small number of pipeline assets, distributors tend to depend on scale, efficiency and contract structures across a broad product base. That can sometimes translate into more stable, if less dramatic, growth profiles, which in turn influence how analysts set and adjust price targets.

Another contextual point is that healthcare distribution is often seen as a defensive area within the market, given the essential nature of prescription medicines and medical supplies even during economic slowdowns. If macroeconomic conditions become more volatile, investors may pay closer attention to defensive characteristics, which could affect valuation multiples for companies like Cardinal Health. At the same time, any sector-specific shocks, such as regulatory shifts focused on drug pricing or distribution practices, could override that defensive positioning and introduce additional volatility.

Investors watching the stock should consider how the current analyst target range, which runs from $208.00 to $275.00, aligns with their own views on Cardinal Health’s risk profile, earnings resilience and position within the healthcare ecosystem. Price targets represent the conclusions of individual research teams based on their specific models and assumptions, not guarantees of future performance. As with any stock, those assessments can change as new information emerges about the company’s operations, the competitive landscape or the broader policy environment.

Overall, the combination of a positive consensus target spread, recent multi-week highs and notable options activity paints a nuanced picture for Cardinal Health. On one hand, analysts as a group still see room for upside; on the other, derivatives positioning and the natural uncertainty around healthcare policy and pricing suggest that the path toward those targets may not be linear. For now, the stock’s standing as a major NYSE-listed healthcare distributor with substantial revenue scale and active analyst coverage ensures that its moves will remain closely watched by market participants.

Cardinal Health in brief

• Name: Cardinal Health Inc.
• Industry: Healthcare distribution and services
• Headquarters: Dublin, Ohio, United States
• Core markets: Pharmaceutical and medical product distribution, primarily in the United States
• Revenue drivers: Drug distribution volumes, medical products and supplies, logistics and related healthcare services
• Listing: New York Stock Exchange, ticker CAH
• Trading currency: U.S. dollar (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.